



To Whom It May Concern:

Over a year ago, our Company needed to significantly reduce our full-time staff to manage a difficult financial situation. That reduction in staff resulted in the elimination of three senior level positions with oversight for regulatory, clinical and manufacturing. The timing was unfortunate as the Company was in the middle of resolving several manufacturing and regulatory issues relating to our lead product candidate HspE7, a drug being developed for human papillomavirus-related diseases.

Our solution was to outsource a number of key functions through part-time consultants, including our regulatory, with Aron Stein, along with several manufacturing support roles. Through Aron's regulatory expertise, we have been able to maintain a high level of contact with the FDA as we continue to press-on with the development of our lead drug. Through introductions from Aron, we were able to tap additional talent in the area of manufacturing support.

Aron has been adept at utilizing his scientific and drug development knowledge to anticipate the U.S. Food and Drug Administration's (FDA) concerns in developing regulatory strategies for our lead compound. He provides thoughtful assessment and insightful solutions, to key regulatory decisions. For example, Aron provided a thorough analysis on the FDA's approach for assessing risk/benefit for two indications (cervical dysplasia and refractory oncology) that were being considered by the Company for future development of HspE7. Because of his input, we were able to make a better informed decision as to which indication to choose.

As a leader, Aron effectively communicates the different deliverables to the team members, and works with individual staff to define the components of the deliverables, ensuring that these components come together to tell the whole story. He's goal-oriented and knows the importance of deadlines. Importantly, Aron has established a collegial relationship with the FDA over the years. The Agency's trust in Aron has provided Nventa with an avenue for open and constructive reviews of our development plans and proposals.

Without reservation, I would recommend Aron to any company who needs a professional in the regulatory and drug development. He's honest and trustworthy. He would be an asset to any organization that needs a seasoned professional who has a proven track record of accomplishments.

Best regards,

Gregory M. McKee
President and Chief Executive Officer
Nventa Biopharmaceuticals Corporation